Literature DB >> 27519412

Melanoma Differentiation-associated Gene 7/IL-24 Exerts Cytotoxic Effects by Altering the Alternative Splicing of Bcl-x Pre-mRNA via the SRC/PKCδ Signaling Axis.

Brian A Shapiro1,2, Ngoc T Vu2, Michael D Shultz1, Jacqueline C Shultz2, Jennifer A Mietla2, Mazen M Gouda2, Adly Yacoub3, Paul Dent2,4,5, Paul B Fisher6,5,7, Margaret A Park8,5, Charles E Chalfant9,2,4,5,10.   

Abstract

Melanoma differentiation-associated gene 7 (MDA-7/IL-24) exhibits cytotoxic effects on tumor cells while sparing untransformed cells, and Bcl-x(L) is reported to efficiently block the induction of cell death by MDA-7/IL-24. The expression of Bcl-x(L) is regulated at the level of RNA splicing via alternative 5' splice site selection within exon 2 to produce either the pro-apoptotic Bcl-x(s) or the anti-apoptotic Bcl-x(L). Our laboratory previously reported that Bcl-x RNA splicing is dysregulated in a large percentage of human non-small cell lung cancer (NSCLC) tumors. Therefore, we investigated whether the alternative RNA splicing of Bcl-x pre-mRNA was modulated by MDA-7/IL-24, which would suggest that specific NSCLC tumors are valid targets for this cytokine therapy. Adenovirus-delivered MDA-7/IL-24 (Ad.mda-7) reduced the viability of NSCLC cells of varying oncogenotypes, which was preceded by a decrease in the ratio of Bcl-x(L)/Bcl-x(s) mRNA and Bcl-x(L) protein expression. Importantly, both the expression of Bcl-x(L) and the loss of cell viability were "rescued" in Ad.mda-7-treated cells incubated with Bcl-x(s) siRNA. In addition, NSCLC cells ectopically expressing Bcl-x(s) exhibited significantly reduced Bcl-x(L) expression, which was again restored by Bcl-x(s) siRNA, suggesting the existence of a novel mechanism by which Bcl-x(s) mRNA restrains the expression of Bcl-x(L). In additional mechanistic studies, inhibition of SRC and PKCδ completely ablated the ability of MDA-7/IL-24 to reduce the Bcl-x(L)/(s) mRNA ratio and cell viability. These findings show that Bcl-x(s) expression is an important mediator of MDA-7/IL-24-induced cytotoxicity requiring the SRC/PKCδ signaling axis in NSCLC cells.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  MDA-7/IL-24, Bcl-x; RNA splicing; alternative splicing; apoptosis; cell death; cell signaling; non-small cell lung cancer; signal transduction

Mesh:

Substances:

Year:  2016        PMID: 27519412      PMCID: PMC5076836          DOI: 10.1074/jbc.M116.737569

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  72 in total

1.  Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing.

Authors:  Christina I Herold; Vijaya Chadaram; Bercedis L Peterson; P Kelly Marcom; Judith Hopkins; Gretchen G Kimmick; Justin Favaro; Erika Hamilton; Renee A Welch; Sarah Bacus; Kimberly L Blackwell
Journal:  Clin Cancer Res       Date:  2011-08-02       Impact factor: 12.531

2.  Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a.

Authors:  Jacqueline C Shultz; Rachel W Goehe; D Shanaka Wijesinghe; Charuta Murudkar; Amy J Hawkins; Jerry W Shay; John D Minna; Charles E Chalfant
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

3.  SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells.

Authors:  Jacqueline C Shultz; Rachel W Goehe; Charuta S Murudkar; Dayanjan S Wijesinghe; Eric K Mayton; Autumn Massiello; Amy J Hawkins; Prabhat Mukerjee; Ryan L Pinkerman; Margaret A Park; Charles E Chalfant
Journal:  Mol Cancer Res       Date:  2011-05-26       Impact factor: 5.852

4.  Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo.

Authors:  Addolorata Maria Luce Coluccia; Silvia Perego; Loredana Cleris; Rosalind Helen Gunby; Lorena Passoni; Edoardo Marchesi; Franca Formelli; Carlo Gambacorti-Passerini
Journal:  Blood       Date:  2003-12-04       Impact factor: 22.113

5.  Ceramide kinase mediates cytokine- and calcium ionophore-induced arachidonic acid release.

Authors:  Benjamin J Pettus; Alicja Bielawska; Sarah Spiegel; Patrick Roddy; Yusuf A Hannun; Charles E Chalfant
Journal:  J Biol Chem       Date:  2003-07-10       Impact factor: 5.157

6.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.

Authors:  L H Boise; M González-García; C E Postema; L Ding; T Lindsten; L A Turka; X Mao; G Nuñez; C B Thompson
Journal:  Cell       Date:  1993-08-27       Impact factor: 41.582

7.  Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.

Authors:  Mitsuo Sato; Melville B Vaughan; Luc Girard; Michael Peyton; Woochang Lee; David S Shames; Ruben D Ramirez; Noriaki Sunaga; Adi F Gazdar; Jerry W Shay; John D Minna
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

8.  Nuclear inhibitor of protein phosphatase-1 (NIPP1) directs protein phosphatase-1 (PP1) to dephosphorylate the U2 small nuclear ribonucleoprotein particle (snRNP) component, spliceosome-associated protein 155 (Sap155).

Authors:  Nobuhiro Tanuma; Sei-Eun Kim; Monique Beullens; Yao Tsubaki; Shinya Mitsuhashi; Miyuki Nomura; Takeshi Kawamura; Kyoichi Isono; Haruhiko Koseki; Masami Sato; Mathieu Bollen; Kunimi Kikuchi; Hiroshi Shima
Journal:  J Biol Chem       Date:  2008-10-08       Impact factor: 5.157

9.  Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24.

Authors:  Sujit K Bhutia; Rupesh Dash; Swadesh K Das; Belal Azab; Zhao-Zhong Su; Seok-Geun Lee; Steven Grant; Adly Yacoub; Paul Dent; David T Curiel; Devanand Sarkar; Paul B Fisher
Journal:  Cancer Res       Date:  2010-04-20       Impact factor: 12.701

10.  The protein kinase DYRK1A phosphorylates the splicing factor SF3b1/SAP155 at Thr434, a novel in vivo phosphorylation site.

Authors:  Katrin de Graaf; Hanna Czajkowska; Sabine Rottmann; Len C Packman; Richard Lilischkis; Bernhard Lüscher; Walter Becker
Journal:  BMC Biochem       Date:  2006-03-02       Impact factor: 4.059

View more
  5 in total

1.  Serine/Arginine-Rich Splicing Factor 3 Modulates the Alternative Splicing of Cytoplasmic Polyadenylation Element Binding Protein 2.

Authors:  James T DeLigio; Shaun C Stevens; Gina S Nazario-Muñoz; H Patrick MacKnight; Keli K Doe; Charles E Chalfant; Margaret A Park
Journal:  Mol Cancer Res       Date:  2019-05-28       Impact factor: 5.852

2.  Ceramide Kinase Inhibition Drives Ferroptosis and Sensitivity to Cisplatin in Mutant KRAS Lung Cancer by Dysregulating VDAC-Mediated Mitochondria Function.

Authors:  Ngoc T Vu; Minjung Kim; Daniel J Stephenson; H Patrick MacKnight; Charles E Chalfant
Journal:  Mol Cancer Res       Date:  2022-09-02       Impact factor: 6.333

Review 3.  Role of MDA-7/IL-24 a Multifunction Protein in Human Diseases.

Authors:  Mitchell E Menezes; Praveen Bhoopathi; Anjan K Pradhan; Luni Emdad; Swadesh K Das; Chunqing Guo; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher
Journal:  Adv Cancer Res       Date:  2018-03-02       Impact factor: 6.242

4.  Splice variants of cytosolic polyadenylation element-binding protein 2 (CPEB2) differentially regulate pathways linked to cancer metastasis.

Authors:  James T DeLigio; Grace Lin; Charles E Chalfant; Margaret A Park
Journal:  J Biol Chem       Date:  2017-09-13       Impact factor: 5.157

5.  miR-203a-3p.1 targets IL-24 to modulate hepatocellular carcinoma cell growth and metastasis.

Authors:  Wei Huo; Min Du; Xinyan Pan; Xiaomin Zhu; Yu Gao; Zhimin Li
Journal:  FEBS Open Bio       Date:  2017-07-10       Impact factor: 2.693

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.